3-(2-methoxy-3-methylphenyl)propionic acid | 74090-49-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(2-methoxy-3-methylphenyl)propionic acid
• 英文别名: Benzenepropanoic acid, 2-methoxy-3-methyl-；3-(2-methoxy-3-methylphenyl)propanoic acid
• CAS: 74090-49-6
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: KKKLXTBVCUPGSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  314.5±27.0 °C(Predicted)
• 密度：
  1.118±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-methoxy-3-methylphenyl)propionic acid 在 palladium on activated charcoal sodium tetrahydroborate 、 硫酸 、 氢气 、 sodium hydride 、 三氟乙酸酐 作用下， 以 甲醇 、 水 、 苯 为溶剂， 反应 67.5h， 生成 2-(methylamino)-5-methoxy-6-methyltetralin
  参考文献：
  名称：

  Derivatives of 5-hydroxy-6-methyl-2-aminotetralin

  摘要：

  The title compounds were designed to provide semirigid congeners of m-tyramine in which the ring position ortho to the phenolic OH is blocked to metabolic hydroxylation. A sequence leading to a key synthetic intermediate, 5-methoxy-6-methyl-2-tetralone, has been developed. In animal test models for dopamine-like effects, the title compounds demonstrated qualitative and quantitative differences from the isomeric 5-methyl-6-hydroxy-2-aminotetralins and from 5,6-dihydroxy-2-aminotetralins. Two of the compounds were potent in a cat cardioaccelerator nerve assay, which involves dopamine receptors.

  DOI：

  10.1021/jm00181a010
• 作为产物：
  描述：

  2-methoxy-3-methylbenzyl alcohol 在 palladium on activated charcoal 哌啶 、 吡啶 、 potassium hypochlorite 、 氢气 、 苄基三丁基氯化铵 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 85.0~115.0 ℃ 、379.21 kPa 条件下， 反应 5.4h， 生成 3-(2-methoxy-3-methylphenyl)propionic acid
  参考文献：
  名称：

  Derivatives of 5-hydroxy-6-methyl-2-aminotetralin

  摘要：

  The title compounds were designed to provide semirigid congeners of m-tyramine in which the ring position ortho to the phenolic OH is blocked to metabolic hydroxylation. A sequence leading to a key synthetic intermediate, 5-methoxy-6-methyl-2-tetralone, has been developed. In animal test models for dopamine-like effects, the title compounds demonstrated qualitative and quantitative differences from the isomeric 5-methyl-6-hydroxy-2-aminotetralins and from 5,6-dihydroxy-2-aminotetralins. Two of the compounds were potent in a cat cardioaccelerator nerve assay, which involves dopamine receptors.

  DOI：

  10.1021/jm00181a010

文献信息

• Compounds for and methods of treating diseases
  申请人：Alterity Therapeutics Limited

  公开号：US11155547B1

  公开（公告）日：2021-10-26

  The present invention provides heterocyclic compounds of formula (I) that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to compounds that modulate iron and to compounds for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA).

  本发明提供了式（I）的杂环化合物，其调节生物金属，并含有这种化合物的药物组合物。本发明特别涉及调节铁元素的化合物，以及用于治疗疾病的化合物，特别是神经系统疾病，如帕金森病（PD）、阿尔茨海默病（AD）、阿尔茨海默型痴呆、亨廷顿病（HD）、肌萎缩侧索硬化（ALS）、额颞叶痴呆（FTD）和多系统萎缩（MSA）。
• Derivatives of 5-hydroxy-6-methyl-2-aminotetralin
  作者：Joseph G. Cannon、Dale L. Koble、John Paul Long、Turkiz Verimer

  DOI：10.1021/jm00181a010

  日期：1980.7

  The title compounds were designed to provide semirigid congeners of m-tyramine in which the ring position ortho to the phenolic OH is blocked to metabolic hydroxylation. A sequence leading to a key synthetic intermediate, 5-methoxy-6-methyl-2-tetralone, has been developed. In animal test models for dopamine-like effects, the title compounds demonstrated qualitative and quantitative differences from the isomeric 5-methyl-6-hydroxy-2-aminotetralins and from 5,6-dihydroxy-2-aminotetralins. Two of the compounds were potent in a cat cardioaccelerator nerve assay, which involves dopamine receptors.